Product Profiles: Autism Spectrum Disorders - Underserved Market Eagerly Anticipates Pipeline Trial Data

Description:

Over the past 6 years, three major events have impacted the autism spectrum disorders market. In 2006, Risperdal became the first drug to receive approval from the US FDA for the symptomatic treatment of irritability in children and adolescents with ASDs. Later, in 2009, the FDA approval Abilify for the same indication. In 2008, generic risperidone launched following Risperdal’s US patent expiry.

Features and benefits

- Overview of marketed and pipeline drugs in clinical development for autism spectrum disorders.
- Analysis of the market positioning of each product approved for the treatment of autism spectrum disorders.
- Assessment of the strengths, weaknesses, opportunities and threats for marketed and late-stage pipeline candidates.
- Summary of the clinical and commercial attractiveness for each of the marketed products.
- Insight from key opinion leaders on marketed and pipeline products.

Highlights

Risperdal and Abilify are the only two products approved for the treatment of autism spectrum disorders (ASDs). Both of these atypical antipsychotics are indicated for the management of irritability symptoms associated with ASDs in the US. Due to the failure of these drugs to address the core symptoms of ASDs, many other drugs are used off-label. Abilify is the most recent entrant to the ASDs market, having received US Food and Drug Administration (FDA) approval in November 2009. The drug’s partial agonism of dopamine receptors unique mechanism of action is considered a key differentiating factor, producing a superior side-effect profile compared to other atypical antipsychotics.

To date, none of the four late-stage pipeline candidates for autism spectrum disorders has publically presented the late-stage Phase II or III trial data necessary for the clinical assessment of these compounds.

Your key questions answered

- What are the key differentiating features of approved therapies for the treatment of autism spectrum disorders?
- How do key opinion leaders perceive available treatments for autism spectrum disorders?
- What opportunities are there for existing players in the autism spectrum disorders market to increase their market share?
- What is the development status of current pipeline candidates development status?
- What clinical trial design are current pipeline candidates following? What do pipeline candidates need to demonstrate in order to be successful?

Contents:

Executive Summary
- Strategic scoping and focus
- Datamonitor key findings
- Related reports

OVERVIEW
- Catalyst
- Summary

MARKET DEFINITION AND OVERVIEW
- Market definition
- Product overview

MARKETED PRODUCT PROFILES
- Abilify (aripiprazole; Bristol-Myers Squibb/Otsuka Pharmaceuticals)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
Risperdal (risperidone; Johnson & Johnson)
Drug profile
Development overview
SWOT analysis
Product positioning
Clinical and commercial attractiveness
PIPELINE PRODUCT PROFILES
CM-AT (Curemark)
Drug profile
Development overview
SWOT analysis
Other drugs in clinical development for autism spectrum disorders
STX-209 (arbaclofen; Seaside Therapeutics)
UCB-MNC (umbilical cord blood mononuclear stem cells; Beike Biotech)
CYP-2001 (carbetocin; Cypress Bioscience)

BIBLIOGRAPHY
Journal papers
Websites
Datamonitor reports

APPENDIX
Contributing experts
Conferences attended
Report methodology

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1841651/

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Product Profiles: Autism Spectrum Disorders - Underserved Market Eagerly Anticipates Pipeline Trial Data
Web Address: http://www.researchandmarkets.com/reports/1841651/
Office Code: SCD2UVAT

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hard Copy:</td>
<td>USD 11500 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 11400</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td>USD 28500</td>
</tr>
<tr>
<td>Enterprise wide:</td>
<td></td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof [ ]
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World